1. Home
  2. VRE vs MESO Comparison

VRE vs MESO Comparison

Compare VRE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRE
  • MESO
  • Stock Information
  • Founded
  • VRE 1949
  • MESO 2004
  • Country
  • VRE United States
  • MESO Australia
  • Employees
  • VRE N/A
  • MESO N/A
  • Industry
  • VRE Real Estate Investment Trusts
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VRE Real Estate
  • MESO Health Care
  • Exchange
  • VRE Nasdaq
  • MESO Nasdaq
  • Market Cap
  • VRE 1.4B
  • MESO 1.4B
  • IPO Year
  • VRE 1994
  • MESO N/A
  • Fundamental
  • Price
  • VRE $14.99
  • MESO $9.96
  • Analyst Decision
  • VRE Buy
  • MESO Buy
  • Analyst Count
  • VRE 4
  • MESO 4
  • Target Price
  • VRE $18.50
  • MESO $18.00
  • AVG Volume (30 Days)
  • VRE 505.0K
  • MESO 197.5K
  • Earning Date
  • VRE 07-23-2025
  • MESO 02-26-2025
  • Dividend Yield
  • VRE 2.13%
  • MESO N/A
  • EPS Growth
  • VRE N/A
  • MESO N/A
  • EPS
  • VRE N/A
  • MESO N/A
  • Revenue
  • VRE $279,630,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • VRE $1.02
  • MESO $178.09
  • Revenue Next Year
  • VRE $3.02
  • MESO $305.06
  • P/E Ratio
  • VRE N/A
  • MESO N/A
  • Revenue Growth
  • VRE 3.92
  • MESO N/A
  • 52 Week Low
  • VRE $13.84
  • MESO $5.78
  • 52 Week High
  • VRE $18.85
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • VRE 49.23
  • MESO 37.18
  • Support Level
  • VRE $14.74
  • MESO $11.70
  • Resistance Level
  • VRE $15.47
  • MESO $12.37
  • Average True Range (ATR)
  • VRE 0.27
  • MESO 0.44
  • MACD
  • VRE 0.02
  • MESO -0.14
  • Stochastic Oscillator
  • VRE 56.16
  • MESO 0.98

About VRE Veris Residential Inc.

Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: